RU2002127778A - IMPROVED METHOD FOR TREATING NEOVASCULARIZATION - Google Patents
IMPROVED METHOD FOR TREATING NEOVASCULARIZATIONInfo
- Publication number
- RU2002127778A RU2002127778A RU2002127778/15A RU2002127778A RU2002127778A RU 2002127778 A RU2002127778 A RU 2002127778A RU 2002127778/15 A RU2002127778/15 A RU 2002127778/15A RU 2002127778 A RU2002127778 A RU 2002127778A RU 2002127778 A RU2002127778 A RU 2002127778A
- Authority
- RU
- Russia
- Prior art keywords
- photosensitive agent
- use according
- inhibitors
- patient
- drug
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000003881 protein kinase c inhibitor Substances 0.000 claims 4
- BBNQQADTFFCFGB-UHFFFAOYSA-N 1,2,4-Trihydroxyanthraquinone Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims 2
- BMGQWWVMWDBQGC-PZFYLCKJSA-N Midostaurin Chemical compound CN([C@@H]1[C@@H]([C@@]2(C)O[C@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-PZFYLCKJSA-N 0.000 claims 2
- RKCAIXNGYQCCAL-UHFFFAOYSA-N Porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 claims 2
- 230000001678 irradiating Effects 0.000 claims 2
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- 101700068305 COP1 Proteins 0.000 claims 1
- 101700037066 COP3 Proteins 0.000 claims 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 1
- 101700086301 Ear1 Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 claims 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 claims 1
- 229960002700 Octreotide Drugs 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 101700007039 PA21 Proteins 0.000 claims 1
- 101700016159 PA22 Proteins 0.000 claims 1
- 101700040243 PA23 Proteins 0.000 claims 1
- 101700071566 PA2A2 Proteins 0.000 claims 1
- 101710031203 PA2CS Proteins 0.000 claims 1
- 101700039989 PA2V Proteins 0.000 claims 1
- 101700014500 PA2X1 Proteins 0.000 claims 1
- 101700036609 PA2X2 Proteins 0.000 claims 1
- 101700024882 PLA2 Proteins 0.000 claims 1
- 101710029814 PLA2G1B Proteins 0.000 claims 1
- 102100001381 PLA2G1B Human genes 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 101710033049 xecG Proteins 0.000 claims 1
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19180700P | 2000-03-24 | 2000-03-24 | |
US60/191,807 | 2000-03-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2002127778A true RU2002127778A (en) | 2004-04-10 |
RU2271222C2 RU2271222C2 (en) | 2006-03-10 |
Family
ID=22707008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002127778/15A RU2271222C2 (en) | 2000-03-24 | 2001-03-22 | Improved method for treatment of neovascularization |
Country Status (21)
Country | Link |
---|---|
US (4) | US20010039438A1 (en) |
EP (1) | EP1265636A2 (en) |
JP (1) | JP2003528926A (en) |
KR (2) | KR20020082487A (en) |
CN (1) | CN100398153C (en) |
AR (1) | AR032151A1 (en) |
AU (2) | AU5040101A (en) |
BR (1) | BR0109499A (en) |
CA (1) | CA2403612A1 (en) |
CZ (1) | CZ20023174A3 (en) |
EE (1) | EE200200547A (en) |
HU (1) | HUP0300347A3 (en) |
IL (1) | IL151833A0 (en) |
MX (1) | MXPA02009351A (en) |
NO (1) | NO20024486D0 (en) |
NZ (1) | NZ521360A (en) |
PL (1) | PL359027A1 (en) |
RU (1) | RU2271222C2 (en) |
UA (1) | UA75350C2 (en) |
WO (1) | WO2001074389A2 (en) |
ZA (1) | ZA200207638B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ521360A (en) * | 2000-03-24 | 2004-07-30 | Novartis Ag | Improved treatment of neovascularization |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
GEP20063755B (en) * | 2001-11-09 | 2006-02-27 | Eyetech Pharmaceuticals | Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases |
JP2006501902A (en) * | 2002-10-03 | 2006-01-19 | ライト サイエンシズ コーポレイション | System and method for exciting photosensitive compounds in ocular tissue |
EP1651161B1 (en) | 2003-08-07 | 2011-10-19 | HealOr Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
US20050043786A1 (en) * | 2003-08-18 | 2005-02-24 | Medtronic Ave, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
FR2867189A1 (en) * | 2004-03-08 | 2005-09-09 | Ludovic Bourre | New compound comprising protein kinase regulator and photoactivatable molecule, useful for treating protein kinase-related diseases, e.g. tumors and inflammation |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
WO2006015016A2 (en) | 2004-07-30 | 2006-02-09 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy and compositions for treating ocular glaucoma |
ZA200802546B (en) | 2005-08-29 | 2009-10-28 | Healor Ltd | Methods and compositions for prvention and treatment of diabetic and aged skin |
US8753673B2 (en) * | 2006-05-23 | 2014-06-17 | Taiwan Liposome Co. Ltd. | Liposome composition for delivery of a therapeutic agent to eyes |
CN102755649A (en) * | 2007-07-30 | 2012-10-31 | 希尔洛有限公司 | Pharmaceutical composition and related methods |
GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
ES2468827T3 (en) | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Pharmaceutical product to prevent or treat disorders accompanied by ocular angiogenesis and / or elevated ocular vascular permeability |
RU2449821C1 (en) * | 2010-09-01 | 2012-05-10 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "МНИОИ им. П.А.Герцена Минздравсоцразвития России") | Method for modifying photodynamic therapy |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4883790A (en) * | 1987-01-20 | 1989-11-28 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US4920143A (en) * | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
DE947222T1 (en) * | 1992-11-20 | 2000-05-04 | Univ British Columbia | Process for activating photosensitive agents |
US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
US5707608A (en) * | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
PL349216A1 (en) * | 1998-12-23 | 2002-07-01 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia |
US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
AU2001227837A1 (en) * | 2000-01-12 | 2001-07-24 | Light Sciences Corporation | Novel treatment for eye disease |
CA2714081C (en) * | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
NZ521360A (en) * | 2000-03-24 | 2004-07-30 | Novartis Ag | Improved treatment of neovascularization |
-
2001
- 2001-03-22 NZ NZ521360A patent/NZ521360A/en unknown
- 2001-03-22 MX MXPA02009351A patent/MXPA02009351A/en not_active Application Discontinuation
- 2001-03-22 HU HU0300347A patent/HUP0300347A3/en unknown
- 2001-03-22 UA UA2002097520A patent/UA75350C2/en unknown
- 2001-03-22 BR BR0109499-8A patent/BR0109499A/en not_active Application Discontinuation
- 2001-03-22 CZ CZ20023174A patent/CZ20023174A3/en unknown
- 2001-03-22 PL PL01359027A patent/PL359027A1/en unknown
- 2001-03-22 AR ARP010101344A patent/AR032151A1/en unknown
- 2001-03-22 AU AU5040101A patent/AU5040101A/en active Pending
- 2001-03-22 WO PCT/EP2001/003265 patent/WO2001074389A2/en active IP Right Grant
- 2001-03-22 CN CNB018071449A patent/CN100398153C/en not_active Expired - Fee Related
- 2001-03-22 JP JP2001572131A patent/JP2003528926A/en active Pending
- 2001-03-22 EP EP01923695A patent/EP1265636A2/en not_active Withdrawn
- 2001-03-22 IL IL15183301A patent/IL151833A0/en unknown
- 2001-03-22 KR KR1020027012287A patent/KR20020082487A/en active Search and Examination
- 2001-03-22 US US09/814,572 patent/US20010039438A1/en not_active Abandoned
- 2001-03-22 RU RU2002127778/15A patent/RU2271222C2/en not_active IP Right Cessation
- 2001-03-22 AU AU2001250401A patent/AU2001250401B2/en not_active Ceased
- 2001-03-22 KR KR1020077027215A patent/KR20070114856A/en not_active Application Discontinuation
- 2001-03-22 CA CA002403612A patent/CA2403612A1/en not_active Abandoned
- 2001-03-22 EE EEP200200547A patent/EE200200547A/en unknown
-
2002
- 2002-09-19 NO NO20024486A patent/NO20024486D0/en not_active Application Discontinuation
- 2002-09-23 ZA ZA200207638A patent/ZA200207638B/en unknown
-
2006
- 2006-07-11 US US11/484,473 patent/US20060263392A1/en not_active Abandoned
-
2007
- 2007-10-18 US US11/975,325 patent/US8158669B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,242 patent/US8862224B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002127778A (en) | IMPROVED METHOD FOR TREATING NEOVASCULARIZATION | |
RU2271222C2 (en) | Improved method for treatment of neovascularization | |
TW448045B (en) | Improved vision through photodynamic therapy of the eye | |
Dolmans et al. | Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy | |
JP3598306B2 (en) | Bioactivation of photosensitizers in blood through skin | |
ES2322030T3 (en) | PROCEDURES AND COMPOSITIONS OF TREATMENT OF NEOVASCULARIZATION AND EYE NERVOUS INJURIES. | |
JP2003528926A5 (en) | ||
AU2001250401A1 (en) | Improved treatment of neovascularization | |
ATE491715T1 (en) | OLIGORIBONUCLEOTIDES AND METHOD FOR USE THEREOF IN THE TREATMENT OF FIBROTIC DISEASES AND OTHER DISEASES | |
CA2296997A1 (en) | Treatment of congestive heart failure | |
AU2002230567A1 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
JP2007505939A (en) | Combinations of VEGF receptor inhibitors with other therapeutic agents | |
EP1570859A2 (en) | Improved treatment of neovascularization | |
RU2211714C2 (en) | Method for treating malignant neoplasms | |
SU1748836A1 (en) | Method for treating the cases of acute and chronic rejection of liver allograft | |
AR122388A1 (en) | METHODS TO TREAT CANCER | |
RU2002101349A (en) | METHOD FOR TREATING CHRONIC PROSTATITIS | |
RU2004104573A (en) | METHOD OF IMMUNO CORRECTION IN CARDIOSURGICAL PATIENTS WITH INFECTIOUS ENDOCARDITIS |